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Recombinant  subunit  vaccines  in general  are  poor  immunogens  likely  due  to  the  small  size of  pep-
tides  and proteins,  combined  with  the  lack  or reduced  presentation  of  repetitive  motifs  and  missing
complementary  signal(s)  for optimal  triggering  of the  immune  response.  Therefore,  recombinant  sub-
unit  vaccines  require  enhancement  by  vaccine  delivery  vehicles  in  order  to  attain  adequate  protective
immunity.  Particle-based  delivery  platforms,  including  particulate  antigens  and  particulate  adjuvants,
are  promising  delivery  vehicles  for modifying  the  way  in  which  immunogens  are  presented  to  both  the
innate  and  adaptive  immune  systems.  These  particle  delivery  platforms  can  also  co-deliver  non-specific
immunostimodulators  as  additional  adjuvants.  This  paper  reviews  efforts  and  advances  of  the  Particle-
based  delivery  platforms  in  development  of vaccines  against  malaria,  a  disease  that  claims  over  600,000
lives  per year,  most  of  them  are  children  under  5  years  of age  in  sub-Sahara  Africa.
©  2015  Elsevier  Ltd. This is an  open  access  article  under  the CC BY  license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Compared to inactivated or live-attenuated whole sporozoites
and whole merozoites, malaria vaccine development strategies
using recombinant subunits and/or synthetic peptides have the
advantage of directing the immune responses toward specific
targets. These strategies, in general, are amenable to large-scale
controlled manufacturing processes leading to the production
of a well-characterized antigen with acceptable purity at a low
cost. Multiple malaria vaccine targets, most of which are anti-
gens expressed on the surface of parasites in liver, blood, and
mosquito stages, have been evaluated for their ability to induce
protective immunity [1]. Promising protective immunity was  often
observed in initial proof-of-concept studies where animals were
immunized with the soluble recombinant proteins formulated with
Freund’s adjuvants. However, the level of protection declined or
was lost in clinical trials when these proteins were formulated
with adjuvants suitable for human use [2,3]. The development of
RTS,S, a recombinant subunit vaccine based on the Plasmodium
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falciparum circumsporozoite protein (PfCSP) present on the sur-
face of infectious sporozoites, has demonstrated the critical roles
of adjuvants and delivery vehicle in order to achieve a significant
efficacy. Despite mounting evidence that recombinant PfCSP was
capable of inducing protective immunity against malaria infection,
it was  not until certain modifications to the formulation were made
that the RTS,S vaccine demonstrated a significant level of protec-
tion against clinical malaria. These modifications include: (i) PfCSP
was fused to and co-expressed with the hepatitis B Surface antigen
(HBsAg) which then self-assembled to form a virus-like particle
(VLP), with multiple copies of PfCSP presented on the particle sur-
face; and (ii) the VLP was  delivered in an oil-in-water emulsion or
a liposomal formulation containing additional immunostimulatory
molecules such as MPL  and QS21 [3,4].
VLPs, stable emulsions, and liposomes belong to a category of
nanoparticle-based delivery platforms that have gained increas-
ing interests in recent years due to their ability to enhance the
immunogenicity of recombinant subunit vaccines (Table 1). A
nano-sized particle displaying high-density repetitive antigens or
epitopes, devoid of invasive pathogenic materials yet permitting
inclusion of desired immunostimulatory molecules, is an ideal
representation that enables incorporation of quality-by-design
concepts during vaccine development. There are multiple benefits
to these platforms. First, a successful immune response, be it
a pathogen or a vaccine, requires the ability of antigens to be
taken up by antigen presenting cells (APCs), processed and pre-
sented to immune effectors. At a size comparable to pathogenic
http://dx.doi.org/10.1016/j.vaccine.2015.09.097
0264-410X/© 2015 Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Table  1
Particle-based delivery platforms.
Type Characteristics* Reference
Particulate antigens Virus-like particles (VLP) Viral capsid protein self-assembled to form a stable core;
exogenous target antigens are displayed repetitively on the surface
by recombinant fusion or chemical conjugation to the viral capsid
protein. A lipid membrane may be present for certain VLPs (e.g.
retrovirus derived VLPs)
[5,64]
Virosomes Lipid-enveloped VLPs without viral capsid core; exogenous target
antigens are displayed repetitively on the envelop surface.
Antigens can be inserted by chemical conjugation to the lipids or
through the natural transmembrane domain present on native
proteins; co-delivery of additional immunostimulants possible
[13]
Self-assembling polypeptide
nanoparticles (SAPN)
Polypeptide core scaffold formed by multiple coiled-coils
oligomerization domains; target antigens are present at the N- and
C-termini of the scaffold polypeptide, and displayed repetitively
on the core surface
[18]
Antigen-carrier conjugates Polypeptides, polysaccharides, or recombinant proteins are
chemically conjugated to a protein carrier, and cross-linked to
form a matrix
[34]
BLPs Micron-sized; peptidoglycan (PGN) matrices derived from food
grade bacteria; target antigens are recombinantly tagged with a
PGN-binding domain and displayed on the matrix surface by
non-covalent interaction with PGN
[8,9]
Particulate Adjuvants Liposomes Lipid bilayer vesicles with an aqueous core; target antigen may be
displayed on vesicle surface, intercalated in lipid bilayer, or
entrapped in aqueous core; co-delivery of additional
immunostimulants
[40,42]
O/W emulsions Nano-to-micron-sized, oil droplets are emulsified in bulk water
phase; target antigens may  interact with the oil droplets by
hydrophobicity or electrostatic force; co-delivery of additional
immunostimulants
[51,65]
W/O  emulsions Nano-to-micron-sized, water droplets are emulsified in bulk oil
phase; target antigens are entrapped in the water droplets
[66]
Iscomatrix A cage-like structure formed at interactions between
phospholipids and saponin-cholesterol micelles; target antigens
are entrapped in the void space of the cage
[67]
Biodegradable polymers Nano-to-micron-sized; bio-degradable synthetic polymers such as
poly (lactic-co-glycolic) acid (PLGA); target antigens are entrapped
within the polymer
[61]
Aluminum salts Micron-sized; porous aggregates of fibrous aluminum hydroxide
or plate-like aluminum phosphate; target antigens are adsorbed to
aluminum salts by electrostatic attractive force or trapped in void
spaces within the aggregates
[68]
* The particles are nano-sized unless otherwise indicated.
microorganisms, the antigen-bearing nanoparticles are more easily
recognized and efficiently taken up by APCs at the site of vaccine
injection [5]. Second, Pattern Recognition Receptors (PRRs) of the
innate immune system are the first line of host defense against a
pathogen. PRRs recognize specific Pathogen-Associated Molecular
Patterns (PAMPs) that leads to the induction of a proinflammatory
response responsible for the induction of both innate and subse-
quently adaptive immunity. Presence of high-density repetitive
epitopes on particle surface facilitates B-cell activation through
cell surface receptor oligomerization and the generation of specific
antibodies with higher affinity [6,7]. Third, prolonged and con-
trolled release of target antigens from the particle will result in a
“depot” effect favoring the induction of lasting immune responses.
Last but not least, the particle may  allow co-delivery of antigen
and immunostimulatory adjuvants such as toll-like receptor (TLR)
agonists to the same APC, ensuring a specific APC activation.
This review aims to summarize efforts and advances in apply-
ing nanoparticle-based delivery platforms to enhance the immune
response of malaria vaccines based on recombinant antigens or
synthetic peptides. The focus is directed toward the works pub-
lished from 2010 and onwards. Though they will not be discussed in
this review, it is worth noting that aluminum salts and Bacterium-
Like Particle (BLP) are also particulate in nature. However, they are
micron-sized, and their modes of action in immune enhancement
differ from those of nanoparticles. To date, aluminum salts do not
appear to provide adequate adjuvanticity to recombinant malaria
vaccine candidates. On the other hand, BLPs have shown some
promising immune enhancement that warrant further exploration
[8,9]. RTS,S, a particulate antigen formulated in particulate adju-
vant, is the subject of a separate review article in this issue [200].
2. Particulate antigens
2.1. Virus-like particles
There are two  main types of VLPs: (i) the non-enveloped VLPs
made of viral capsid proteins that self-assemble into stable struc-
tures. The vaccine target antigens can be recombinantly fused to
the viral protein and displayed on the particle surface; and (ii)
enveloped VLPs harboring a lipid membrane with the vaccine target
antigens anchored at the surface. Among enveloped VLPs there are
two categories: those having a core of proteins forming a capsid-
like structure surrounded by a lipid membrane, and those devoid
of a protein core and having only a lipid membrane with the target
antigens embedded, such as the influenza virosomes. In the latter
case, target antigens could be recombinant proteins or synthetic
peptides that are conjugated to lipid tails for membrane anchoring,
or it could be native proteins with their own  transmembrane and
cytoplasmic domain.
Utilizing recombinant expression in Tobacco plants as a plat-
form technology, Jones et al. constructed an expression vector
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encoding Pfs25, a P. falciparum ookinete surface protein and a
transmission blocking vaccine candidate, fused to the coat protein
(CP) of Alfalfa mosaic virus [10]. The purified recombinant prod-
uct composed of the Pfs25-CP fusion protein and two  truncated
CP polypeptides, in planta co-assembled to form VLPs 20 nm in
diameter. The requirement of the truncated viral coat protein in the
assembly process is reminiscent of RTS,S, where assembly of PfCSP-
HBsAg VLP also required truncated HBsAg [3]. Interestingly, mice
immunized with Pfs25-CP VLPs formulated in Alhydrogel® elicited
high-titer, long-lasting transmission blocking antibodies even with
a single vaccination dose. A Phase 1 trial with Pfs25-CP VLP formu-
lated with Alhydrogel® has been conducted in healthy adults in the
USA though the results are not yet published [101].
Enhancement of antibody responses by VLP was also demon-
strated in study in rhesus monkeys immunized with soluble and
particulate versions of a vaccine based on Plasmodium vivax CSP,
a.k.a CSV [11]. Four groups of rhesus monkeys were immunized
with two doses each of a soluble form of the vaccine (VMP001)
or the particulate version (CSV-S,S). The latter are VLPs that are
formed by fusing VMP001 to hepatitis B Surface antigen (CVS-S)
and co-expressing with free HBsAg to form CSV-S,S. While both
vaccines, formulated with AS01 which consists of MPL, QS21 and
liposomes, induced robust cellular and humoral responses, CSV-
S,S generated higher antibody titers, particularly with regard to a
potentially protective B cell epitope.
Another way to present target antigens on the surface of a VLP is
by chemical conjugation of a recombinant antigen to the surface of a
preassembled VLP. A well tested example of this principle is the VLP
formed from the capsid protein of the bacteriophage Q· The amino
group of the surface exposed Lysine residues are reacted with a
bi-functional chemical cross-linker which is subsequently reacted
with the target antigen engineered to contain a reactive Cysteine
residue. The resulting VLP products present repetitive arrays of
the target epitope on the particle surface. This platform has been
evaluated extensively in therapeutic vaccines such as ones against
nicotine dependence, hypertension, and Alzheimers diseases [12].
The Qb VLP has also been used as a core to present multiple copies
of recombinant Pfs25 on its surface. Immunizing mice with the
Pfs25-Q VLP, formulated with or without Alhydrogel®, induced
anti-Pfs25 antibody titers higher than that of Pfs25-EPA conju-
gates. The antibodies displayed transmission blocking activity, and
stronger IgG2 and IgG3 titers indicating a Th1 response induced by
Pfs25-Qb VLP [201].
Virosomes, enveloped VLPs constituted of phospholipids and
viral proteins, may  incorporate the target antigens by coupling
them to lipid components of the envelope. Although virosomes
can be produced from a variety of enveloped viruses, the influenza
virus has been the dominant substrate for producing virosome-
based vaccines [13]. The virosomal delivery platform benefited
from an extensive human safety profile, as demonstrated over
the last 20 years in adults as well as children, elderlies, and
immune-compromised populations [14,15]. Early efforts of con-
jugating virosomes with peptides derived from repeat region of
PfCSP and an ectodomain of the P. falciparum apical membrane
antigen-1 (PfAMA1), a micronemal protein involved in merozoite
invasion led to several clinical trials. When evaluated indi-
vidually, both PfCSP-virosome (PEV302T) and PfAMA1-virosome
(PEV301T) formulations demonstrated excellent safety, tolerabil-
ity and immunogenicity, though none of the participants were
protected against blood stage infection in a challenge study [13].
However, when PEV302T and PEV301T were administered in com-
bination, a reduction in the malaria incidence rate was  observed
in children aged 5–9 years old, indicating the value of a multiva-
lent vaccine approach [16]. The virosome was also used to deliver
GMZ2, a recombinant fusion protein consisting of the N-terminal
portion of the P. falciparum Glutamate Rich Protein (PfGLURP)
and C-terminal fragment of the P. falciparum Merozoite Surface
Protein 3 (PfMSP3). Although the antibody titer elicited by the
unadjuvanted GMZ2-virosome conjugate was  merely comparable
to the titer by GMZ2 formulated with alum [17], the result seemed
encouraging for 2 reasons: (i) In addition to small peptide focusing
on key epitopes (also called mimotopes), the virosome is a versa-
tile platform allowing also the delivery of small-to-large size (∼2 to
100 kDa) recombinant antigens, some in dimeric or trimeric forms;
and (ii) Virosome platform still has the potential to further enhance
immunity if additional and relevant adjuvants are inserted into
the lipid membrane or packaged within the aqueous core of the
virosomes.
2.2. Self-assembling polypeptide nanoparticles (SAPNs)
Self-Assembling Polypeptide Nanoparticles (SAPN) are based
on the alpha-helical coiled-coil oligomerization motifs present in
protein sequences that allow them to self-assemble into well-
defined ordered structures. The basic building block of the SAPN
is a monomeric polypeptide chain containing one pentameric
and one trimeric coiled-coil oligomerization domains. Driven by
these domains, about 60 polypeptide chains self-assemble into an
ordered structure with icosahedral symmetry, exposing both N-
and C terminal ends on the surface [18]. Extending the polypeptide
chain with target epitopes would allow presentation of the target
epitopes in a repetitive array on the particle surface.
To test this novel concept for development of malaria vaccines,
Kaba et al. designed and recombinantly produced a polypeptide
chain based on the pentameric coiled-coil sequence of cartilage
oligomeric matrix protein (COMP), a de novo-designed trimeric
coiled-coil, and a B cell immunodominant repeat epitope of Plas-
modium berghei CSP that assembled into ∼25 nm particles [19].
Immunized mice generated CD4+ T cell-dependent, high-titer,
high-avidity long-lasting antibody responses that were capable of
protecting mice challenged with P. berghei sporozoites. In order to
develop the SAPN platform for human use, the pentameric coiled-
coil forming sequence was switched from the COMP domain to a de
novo designed Tryptophan-zipper to prevent possible cross reac-
tivity [20,21]. Interestingly the replacement of the COMP sequence
resulted in a loss of immunogenicity and protective efficacy in mice,
which was restored by introducing a universal helper T cell epitope
PADRE into the trimeric coiled-coil domain. These second genera-
tion constructs were designed to expose the immunodominant B
cell epitope from the repeat region of P. falciparum CS at the surface
of the SAPNs and also included three P. falciparum CD8+ epitopes
within the scaffold of the nanoparticle. The long-lasting antibodies
elicited by the new SAPNs were capable of protecting mice chal-
lenged with Tg-Pb/PfCSP, a transgenic P. berghei parasite expressing
PfCSP on its sporozoite surface [20]. Using SAPNs that contained
heterologous B cell epitopes and/or lacked the CD8 epitopes, pro-
tection was demonstrated to be mediated via both antibodies and
CD8 T cells. The process to produce these SAPNs is amenable to
cGMP manufacturing [22] and they are currently being developed
further for human testing.
2.3. Antigen-carrier conjugates
Development of chemical conjugate vaccines, in general, is
based on early work using non-immunogenic targets or haptens
chemically conjugated to a “carrier protein”. Active immuniza-
tion with hapten-carriers enabled production of hapten specific
antibodies due to appropriate communication between T cells
and B cells [23]. These observations supported production of
chemically conjugated polysaccharide vaccines that switch T
cell-independent antigen presentation of polysaccharide moieties
to T cell-dependent antigens for use in licensed vaccines for
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predominately young children against Neisseria meningitides,
Haemophilus influenza type b and Streptococcus pneumoniae [24].
Various carriers are used in these commercial vaccines including
cross reactive material of diphtheria detoxified toxin bearing an
amino acid substitution, identified as CRM197; Tetanus toxoid (TT),
and meningococcal outer membrane protein complex (OMPC) [25].
Encouraging results were obtained by conjugating Pfs25 to
OMPC: the conjugation significantly enhanced the antibody titers in
mice, rabbits, and non-human primates. Chemical coupling did not
seem to affect functional epitopes, as the correlation between the
conjugate-induced antibody titres and their transmission reducing
activities was similar to that induced by soluble Pfs25 formu-
lated with Montanide® ISA51, a water-in-oil formulation. More
interestingly, the antibody response induced by the conjugate was
sustained for 2 years, and recalled by a booster dose of Pfs25 for-
mulated with an aluminum adjuvant [26]. It was noted that OMPC
differs from other carriers in that its proteins are present in a liposo-
mal  form containing lipids, including lipopolysaccharide, a natural
adjuvant. The potential for development of a Pfs25-OMPC chemical
conjugate vaccine is under further investigation.
A well-defined protein carrier, the recombinant Pseudomonas
aeruginosa detoxified toxin, ExoProtein A (rEPA) produced in
Escherichia coli, has also demonstrated the capacity of immune
enhancement [27]. Although rEPA is not yet a component of any
licensed vaccine, it appears to be safe in humans including infants
[28–31]. Early preclinical studies evaluating the immunogenicity
of chemically conjugated recombinant Pfs25 and Pfs28 to rEPA
formulated on Alhydrogel® demonstrated an enhanced functional
antibody response, which was further enhanced by adding CpG
[27,32,33]. A pilot-scale production process was developed to man-
ufacture a Pfs25-EPA conjugate in compliance with current good
manufacturing practices [34], and a Pfs25-EPA/Alhydrogel® formu-
lation was tested in Phase 1 trials in US and Mali adults [102,202].
Of particular interest, the Pfs25-EPA chemical conjugate appears
as a nanoparticle in solution with a similar diameter to VLPs of
the RTS,S vaccine [34]. A second Phase 1 trial in US and Mali
adults is in progress testing a second generation of Pfs25-EPA con-
jugate vaccine, using a recombinant Pfs25 protein without any
heterologous amino acids, alone and in combination with a recom-
binant subdomain of a P. falciparum gamete surface protein Pfs230
chemically conjugated to EPA [103,203]. Unfortunately, chemical
conjugation of larger recombinant proteins may  not provide a sim-
ilar immunological benefit. For example, chemical conjugation of
two recombinant proteins larger than 40 kDa to rEPA failed to pro-
vide any significant enhancement in immunogenicity when tested
in small animals [35] [204].
Chemical conjugation of the nontoxic cholera toxin B subunit
with recombinant Pvs25, a Pfs25 ortholog on P. vivax zygote surface,
has been reported to increase the transmission reducing efficacy
against P. vivax [36]. Miyata et al. also developed a novel strategy
to increase immune responses by creating genetic fusion proteins
to target specific APCs. The fusion complex was composed of three
physically linked molecular entities: (i) A vaccine antigen, (ii) A
multimeric alpha-helical coiled-coil core, and (iii) An APC-targeting
ligand linked to the core via a flexible linker. Immunization of mice
with the tricomponent complex fused to Pvs25 induced a robust
antibody response and conferred substantial levels of P. vivax trans-
mission blockade [37].
Epitope repetition within conjugates, in addition to particle
formation is likely to be another mechanism of immune enhance-
ment. Kubler-Kielb et al. demonstrated that polymerizing Pfs25
by chemical conjugation to itself improved Pfs25 immunogenic-
ity and response longevity in mice [38]. The multimeric Pfs25 core,
in addition to its own merit as a target antigen, was  also used as a
carrier for conjugation with the central repeats of PfCSP. The conju-
gation enhanced immunogenicity of the PfCSP repeats in mice [39],
likely due to the epitope repetition and the particulate nature of
the conjugates.
3. Particulate adjuvants
3.1. Liposomes
Liposomes are self-assembling spherical vesicles composed of
a phospholipid bilayer enclosing an aqueous core. Liposomes can
also be made as multilamellar in which multiple concentric lipid
bilayers are separated by aqueous layers. Liposomes have versatile
ways to deliver target antigens and additional immunomodulators
as adjuvants. Depending upon chemical and biochemical proper-
ties, water-soluble target antigens can be entrapped within the
aqueous phase, and lipophilic molecules can be intercalated within
the lipid bilayer. Antigens and adjuvants can also be attached to
the surface of liposomes by adsorption, covalent conjugation, and
electrostatic interactions. Liposomes have been broadly applied to
enhance T and B cell responses to subunit vaccines candidates,
including several being evaluated in humans [4,40–42].
The most advanced application of the liposomal delivery sys-
tem in malaria vaccine development is AS01, an Adjuvant System
comprised of liposome, QS21, and MPL, a TLR4 agonist. In comple-
tion of a multi-center Phase 3 trial of RTS,S/AS01 involving >15,000
children including 6000 infants in malaria endemic regions, the
adjuvant has an extensive safety profile [200]. In addition to RTS,S,
several recombinant malaria antigens formulated with AS01 have
been evaluated in humans. These include LSA-NRC, a recombi-
nant protein comprised of N-and C-terminal regions and two of
the central repeats of P. falciparum Liver Stage Antigen 1 and a
candidate vaccine to block merozoite egress from hepatocytes, in
a Phase 1 trial in US adults followed by a Phase 2a sporozoite
challenge [43]; AMA1, a recombinant ectodomain of P. falciparum
merozoite apical membrane antigen 1, in a Phase 1 trial in US
adults followed by a Phase 2a sporozoite challenge [44]; and
MSP142, the 42 kDa N-terminal region of P. falciparum merozoite
surface protein 1, in a Phase 1 trial in US adults followed by a
second Phase 1 trial in Kanyan adults [45]. All formulations demon-
strated reassuring safety profiles. Despite the fact that none of
these formulations showed any protection in challenge studies
(for PfLSA-NRC and PfAMA1) or in growth inhibition assay (for
PfMSP142), all have elicited high titers of specific antibodies. In
addition, PfLSA-NRC/AS01 formulation induced higher CD4+ T cell
response than did PfLSA-NRC formulated with AS02, another Adju-
vant System and an oil-in-water emulsion also containing MPL  and
QS21 (see Section 3.2), indicating the role of liposomal formulation
in induction of cellular responses [43]. However, no significant dif-
ference was found in CD4 responses induced by PfAMA1/AS01 or
by PfAMA1/AS02 [44].
The PfAMA/AS01 and PfAMA1/AS02 were also evaluated in UK
healthy adults, followed by a challenge with blood-stage parasites
[104]. Also being evaluated in human trials were PfCelTOS/AS01
[105] and PvCSP/AS01 [106], two  vaccine candidates to block
sporozoite invasion of hepatocytes by P. falciparum and P. vivax
parasites, respectively. In both studies the participants receiving
the full intended dose were challenged with falciparum or vivax
sporozoites. Anticipated analysis will shed light whether protec-
tive efficacies, if any, are associated with B cell or T cell responses,
and the role of the adjuvant in these responses.
GLA-LSQ is a novel liposomal adjuvant consisting of liposome,
QS21 and Glucopyranosyl Lipid A (GLA). Since GLA is a known TLR4
agonist [46], GLA-LSQ is expected to have similar adjuvanticity
as AS01. With a recombinant full-length Pf CSP produced in Pseu-
domonas fluorescens expression platform, NOE et al. evaluated the
solubilized rPfCSP in various delivery systems including GLA-LSQ,
GLA in stable emulsion (GLA-SE), and aluminum salts, with the
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intention to select one for human use. Whereas the GLA-LSQ and
GLA-SE formulations were comparable in antibody induction, in
functional assays including in vitro inhibition of sporozoite invasion
and in vivo protection against Tg-Pb/PfCSP sporozoite challenge,
rPfCSP/GLA-LSQ formulation was a clear winner in induction of
cellular and lasting antibody responses. Partial protection against
sporozoite challenge was observed, and it would be interesting
to know whether the protected animals had higher humoral and
cellular responses [47].
While it is unclear how liposomes in AS01 and GLA-LSQ interact
with the target antigens, the cationic liposomal adjuvants clearly
attract target antigens with opposite charges through electrostatic
interaction. One of these is CAF01, a novel liposomal adjuvant
composed of cationic lipid vesicles stabilized with a glycolipid
immunostimulant TDB, a synthetic analogue of mycobacterial cell
wall. A CAF01 formulated vaccine candidate against tuberculosis
was shown to be safe and tolerable in humans, and induced strong
lasting T-cell responses. However, there was no detectable antibody
responses in humans, in contrast to observation in preclinical ani-
mal  studies [42]. CAF01 has also been used to formulate PyMSP119
[48], a recombinant protein based on the 19 kDa C-terminal region
of Plasmodium yoelii MSP1, and DBL4-ID4, a recombinant subunit
of P. falciparum VAR2CSA and a vaccine candidate to protect women
against placental malaria [49]. PyMSP119/CAF01 induced signifi-
cantly higher IgG1 and IgG2 antibodies in mice than did the alum
formulation, and conferred a stronger partial protection in mice
from a blood stage parasite challenge. In the DBL4-ID4/CAF01
study, the DBL4-ID4 was also formulated with 2 other adju-
vants: Alhydrogel and Montanide ISA720, a water-in-oil emulsion.
Although antibody titers induced by all 3 formulations were similar,
the DBL4-ID4/CAF01 induced IgGs displayed a stronger inhibition
of infected erythrocytes binding to chondroitin sulphate proteogly-
cans, and a stronger binding to the target antigen DBL4-ID4.
Interbilayer-crosslinked multilamellar vesicle (ICMV) is another
type of liposomal delivery system that shows promise. Moon
et al. reported enhanced antigen-specific humoral responses when
ICMVs were used to co-deliver a TLR4 agonist along with PvCSP
that was either entrapped within the vesicle or entrapped as well
as displayed on the surface of the vesicles ICMV [50]. The result-
ing ∼180 nm particles elicited antibodies that were 9-fold higher
in the formulation with entrapped and surface-displayed PvCSP
compared to the group which did not have antigen on the sur-
face. This vaccine delivery method allowed dose-sparing, generated
a more balanced Th1/Th2 response with high avidity long-lasting
antibodies. The response correlated with the induction of Tfh cells in
germinal centers that formed adjacent to the vaccination site. These
observations seem consistent with the mechanisms of immune
enhancement by a particulate delivery system.
3.2. Stable emulsion
Emulsion-based nanoparticle adjuvants include oil-in-water
(O/W) emulsions that interact with target antigens mainly by
hydrophobic or electrostatic forces, and water-in-oil (W/O) emul-
sions that entrap target antigens in water droplets. They have been
widely used in vaccine development, and the O/W emulsion MF59
and AS03, and W/O  emulsion Montanide® ISA51 are components
of several licensed vaccines [51].
Following unsatisfactory outcomes in animal studies with MF59
adjuvanted malaria antigens including P. falciparum AMA1, MPS1,
SERA, Pfs25, and P. vivax Duffy-binding protein, no further clinical
development was  justified with the adjuvant [52]. Despite superb
immune-enhancement offered by Montanide® ISA51 and a sim-
ilar W/O  emulsion Montanide® ISA720, the adjuvants ceased to
be the choice for clinical development due to high rate of local
reactogenicity and unexpected systemic reactions in Phase 1 trials
[53,54]. On the other hand, AS02, an O/W emulsion with additional
immunostimulants MPL  and QS21, has been shown in clinical trials
to enhance immune responses of multiple malaria antigens includ-
ing P. falciparum AMA1, MSP1 and LSA1, though the adjuvant did
not increase their protective efficacy [43,44]. Although AS02 was
the initial adjuvant that delivered RTS,S with proven clinical effi-
cacy, it was outperformed by RTS,S/AS01 formulation for induction
of humoral and cellular immunity, and protective efficacy [4,55].
GLA-SE, an O/W emulsion containing TLR4 agonist, was
expected to have similar adjuvanticity as AS01 due to their simi-
lar composition except for lacking QS21 in GLA-SE. Indeed, GLA-SE
has a demonstrated capacity to elicit strong Th1 type immune
responses. PbCSP and PfCelTOS formulated with GLA-SE induced
higher level of IgG2 antibodies and more INFγ-producing cells in
mice [56,57]. GLA-SE also has a broad safety profile in humans:
It has been injected in hundreds of humans in multiple Phase 1
trials evaluating vaccine candidates against various diseases. The
completed or currently on-going Phase 1 trials with GLA-SE formu-
lated recombinant malaria antigens include PfCelTOS, PfAMA1, and
PfP27A, a synthetic polypeptide corresponding to the unstructured
domain of P. falciparum Trophozoite exported protein 1 (Tex1)
[107]. While results of these trials are not yet published, the attempt
has been made to further increase the immune enhancing capacity
of GLA-SE by inclusion of additional TLR7/8 agonists, such as R848.
Unfortunately PvSCP formulated with GLA/R848-SE induced lower
humoral and cellular responses in mice [58].
3.3. Others
Several other particulate delivery systems, including ISCOMs
and biodegradable polymers, caught interest of malaria vaccine
developers.
ISCOMs are cage-like particles composed of phospholipids,
saponin-cholesterol micelles and the antigens incorporated into
particles through hydrophobic interaction, which requires a
hydrophobic tag if the target antigen is hydrophilic [59]. Subse-
quently, by using different lipids, Isomatrix® became a versatile
adjuvant system that can entrap any type of target antigens, deliver
the target antigens to APCs, and enhance both B cell and T cell
responses in multiple species. Isomatrix® has been applied to over
one thousand volunteers in Phase 1 and Phase 2 trials evaluat-
ing prophylactic and therapeutic vaccines, and was  shown to be
well tolerated. Regarding malaria antigens, Przysiecki et al. evalu-
ated immunogenicity of (NANP)6-OMPC/MAA, an alum adsorbed,
OMPC-conjugated peptide corresponding to the central repeats of
PfCSP, with and without Isomatrix®. In in-bred mice, addition of
Isomatrix® to the alum formulation did not have much effect on
antibody titer, while in rhesus monkeys, addition of Isomatrix® in
formulation induced a long-lived high-level anti-repeat antibodies
compared to the animals immunized with the formulation with-
out Isomatrix® [60]. The observations prompted cautions of using
alum-formulation as a bench marker for adjuvant selection in mice,
as the species and the adjuvant is widely used in initial proof-of-
concept studies.
Biocompatible and biodegradable polymeric nanoparticles may
represent a promising new technology for improved immune
responses [61]. Their ability to sustain and control the release of
the entrapped antigens and their delivery to APCs raised hope for
eliciting long-lasting immune responses. Among a wide variety of
synthetic polymers used to prepare nanoparticles, poly (lactic-co-
glycolic) acid (PLGA) has been evaluated extensively and is already
in several FDA-approved therapeutic delivery devices. By emul-
sifying PLGA and maleimide-activated lipids, Moon et al. created
new PLGA particles enveloped with a lipid bilayer, which allowed
covalent conjugation of thiolated PvCSP on the particle surface [62].
The resulting PvCSP-NP elicited durable antibody with significantly
Y. Wu et al. / Vaccine 33 (2015) 7518–7524 7523
higher titers and more balanced Th1/Th2 responses, compared to
the PvCSP monomer. Antibody titers raised by PvCSP-NP were able
to agglutinate P. vivax sporozoites, and exhibited higher avidity
and affinity toward the recombinant protein. Using a derivative
of PLGA, Dinglasan et al. prepared a nano-to-micron-sized parti-
cle incorporated with recombinant AnAPN1, an Anopheles gambiae
aminopeptidase in mosquito midgut and a TBV candidate [63].
Immunization of the An-APN1 loaded particle induced functional
antibodies, as measured by direct feeding of mosquitoes on immu-
nized mice challenged with P. berghei, even 6 months after a single
dose of vaccination.
4. Reflection and conclusion
Since a strong safety profile in humans is paramount for devel-
opment of prophylactic vaccines, a rather conservative approach
has been taken in adjuvant/delivery selection for recombinant
subunit-based malaria vaccine candidates. Nearly all clinical trials
with recombinant malaria antigens started with aluminum salts as
the adjuvant. Now it has become a consensus that recombinant
subunit vaccines are unlikely to achieve desired protective effi-
cacy without an appropriate delivery vehicle that includes not only
adjuvant but also a proper antigen presentation format. Particu-
late delivery of vaccine antigens is advantageous as it can simulate
a pathogen-mimicry by presenting the proteins as larger moi-
eties, allowing more efficient uptake by APCs, stimulating innate
immune responses through Pattern Recognition Receptors (PRRs),
and providing depot effect for lasting responses. The licensure
of particle-based vaccines such as HPVs and the accumulation of
safety data in other vaccines in clinical trials has raised the hope
of applying such delivery systems in malaria vaccine development
without compromising the safety precaution.
Selection of a suitable delivery platform for a particular malaria
antigen has been and will likely remain to be empirical. There are
still technical hurdles in optimizing the delivery platforms, par-
ticularly with regard to particulate antigens such as VLPs, SAPNs,
and antigen-carrier conjugates. There seems to be a size and den-
sity limit to the target antigens to be displayed on the particle
surface. To remedy this we need a clear understanding as well as
tools for characterization of the functional epitopes or subdomains
within the target antigen, and their native conformation. The pro-
cesses and conditions to preserve the native conformation during
the synthetic or recombinant production of the target epitope or
antigen have to be empirically determined. Other needs that have
to be empirically determined are the processes and conditions to
increase the antigen to core/carrier loading ratios. Finally during
selection of the delivery platforms, the immune status of the tar-
get population needs to be considered. New born babies and young
infants may  have different adjuvant requirement as older children
and adults. Vaccine must be “tailored” according to the immune
status of subjects to be vaccinated.
While animal models are always used in initial proof-of-concept
studies, the definitive evaluation of a delivery platform has to be
trials conducted humans. It is an exciting time as multiple clini-
cal trials have been conducted or are on-going to evaluate several
particle-based delivery of subunit malaria antigens. Outcomes of
these trials will not only help the selection of safe and potent deliv-
ery vehicles, but will also shed light on whether and/or how animal
models predict the immune response and the protective efficacy in
humans.
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